Tackling TAMs for Cancer Immunotherapy: It’s Nano Time
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) is characterized as a highly complex environment surrounding tumors. The interactions between cancer cells/non-cancerous cells and cells/non-cell components within the TME create a supporting soil for tumor initiation, development, and metastasis. Among the cell types, tumor-associated macrophages (TAMs) have gained attention due to crucial roles in supporting tumors and conferring therapy resistance. Recent developments in nanotechnology raise opportunities for the application of nano targeted drug delivery systems (Nano-TDDS) in cancer therapy. Here we focus our discussion on the current knowledge of TAMs, and describe recent examples of Nano-TDDS-based TAM modulation, highlighting the formulation design for conquering in vivo delivery barriers associated with the TME and the potential of these strategies for clinical translation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“The components of tumor microenvironment (TME) mainly include [1]: 1) different cell types such as tumor cells, immune cells, and stromal cells [e.”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Additionally, the crosstalk between different cell types via the production of soluble signaling mediators leads to tumor immune escape; as a consequence, the immunosuppressive TME causes dramatic resistance to currently available immune-based therapies [6].”
BackgroundCancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523 · cited 1×
“PEG) to improve pharmacokinetic profiles [51].”
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840 · cited 3×
“indoleamine 2,3-dioxygenase 1 (IDO-1), cyclooxygenase type 2 (COX‐ 2), programmed death-ligand 1 (PD-L1), and arginase-1] [15].”
BackgroundThe immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · cited 3×
“The roles of TAMs as immunosuppressive regulators in tumor immunity and immunotherapy have been further described elsewhere [7] [8].”
BackgroundInflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847 · cited 1×
“IL-1β, IL-6, and TNF-α), which can support the survival, proliferation and activation of ECs for promoting angiogenesis in favor of tumor growth (Figure 1) [29].”
BackgroundMacrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 1×
“Besides, hypoxia may regulate the polarization of TAMs towards pro-tumoral (M2) phenotype [36].”
BackgroundZanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“For example, tumor cells produce macrophage colony stimulating factor (MCSF) for deforming TAM polarization from M1 to M2 [67].”
BackgroundLin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398 · cited 1×
“Hypoxic TAMs upregulate pro-angiogenic and immunosuppressive cytokines to promote tumor angiogenesis, metastasis, and immune evasion [35].”
BackgroundRodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 1×
“This hypoxic heterogeneity furthers tumor progression using a variety of pathways, such as the induction of immune escape, promotion of glycolysis, suppression of apoptosis, and resistance to therapy [33].”
BackgroundTargeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Transport of drugs from blood vessels to tumour tissue
Dewhirst, M. W., & Secomb, T. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.93 · Cited by 749 · cited 1×
“For example, the dense ECM and tortuous blood vessels hinder the trafficking of therapeutic agents to tumor cells [4].”
BackgroundTherapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620 · cited 1×
“It has also been reported that angiogenic ECs stimulated by TAMs can upregulate the autocrine angiopoietin 2 (ANGPT2) signaling pathway, which in turn loosens the association of pericytes with blood vessels, leading to the vascular leakage in tumors [30].”
BackgroundInteraction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117 · cited 1×
“Although therapeutic agents penetrate into tumors, they are often inactivated inside the hypoxic/acidic environments [5].”
Background
Cited by
Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy
Gao, J., Liang, Y., & Wang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888713 · Cited by 555
Han, S., Bao, X., Zou, Y., Wang, L., Li, Y., Yang, L., Liao, A., Zhang, X., Jiang, X., Liang, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2697 · Cited by 310
Self-citationThe role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
Multistage ROS-Responsive and Natural Polyphenol-Driven Prodrug Hydrogels for Diabetic Wound Healing
Ni, Z., Yu, H., Wang, L., Huang, Y., Lu, H., Zhou, H., & Liu, Q. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c15686 · Cited by 137
Poh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106
Metadata
- Authors
- Yang, Y., Guo, J., & Huang, L.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 41
- Issue
- 10
- Pages
- 701-714
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W3087550005
- Cited by
- 98
- References
- 21
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.